Rhenman & Partners Asset Management’s Spark Therapeutics, Inc. Common Stock ONCE Stock Holding History

Rhenman & Partners Asset Management’s Portfolio ONCE Stock Details ONCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-10,000	Closed	-$1.02M	–	97
2019 Q2	$1.02M	Buy	+10,000	New	+$1.08M	0.11%	75
2019 Q1	–	Sell	-88,302	Closed	-$3.46M	–	100
2018 Q4	$3.46M	Sell	88,302 -49,389	-36%	-$2.14M	0.4%	64
2018 Q3	$7.51M	Sell	137,691 -39,909	-22%	-$2.73M	0.75%	53
2018 Q2	$14.7M	Buy	177,600 +110,000	+163%	+$8.49M	1.5%	30
2018 Q1	$4.5M	Sell	67,600 -2,600	-4%	-$150K	0.55%	58
2017 Q4	$3.61M	Buy	+70,200	New	+$5.04M	0.49%	64

Other funds holding ONCE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

Rhenman & Partners Asset Management's ONCE Position: Q3 2019 in Review

Rhenman & Partners Asset Management sold out of Spark Therapeutics, Inc. Common Stock (ONCE) in Q3 2019, closing a stake of 10,000 shares — an estimated $1.02M sold.

Rhenman & Partners Asset Management first reported a position in ONCE in Q4 2017 and held it in 6 quarters. The position peaked at $14.7M in Q2 2018. 184 funds tracked by Wall St. Rank hold ONCE as of Q3 2019.

Rhenman & Partners Asset Management reported no remaining Spark Therapeutics, Inc. Common Stock position as of Q3 2019 after selling out during the quarter.
Rhenman & Partners Asset Management sold 10,000 Spark Therapeutics, Inc. Common Stock shares in Q3 2019, an estimated $1.02M.
Rhenman & Partners Asset Management first reported a position in Spark Therapeutics, Inc. Common Stock in Q4 2017 and held it in 6 quarters.
Rhenman & Partners Asset Management's Spark Therapeutics, Inc. Common Stock position peaked at $14.7M in Q2 2018.
184 funds tracked by Wall St. Rank held Spark Therapeutics, Inc. Common Stock as of Q3 2019.

Based on Rhenman & Partners Asset Management's 13F filing for Q3 2019, filed 16 Oct 2019.